睿知中国医院研究地图
候选清单

正在招募乳腺癌III期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

ClinicalTrials.gov 上登记的一项乳腺癌开放试验。牵头方不是本站收录的医院;本站收录的 13 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 13

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心青岛大学附属医院Affiliated Hospital of Qingdao University青岛医院页面
  2. 研究中心安徽省肿瘤医院Anhui Provincial Cancer Hospital合肥医院页面
  3. 研究中心北京医院Beijing Hospital北京医院页面
  4. 研究中心中国人民解放军总医院Chinese PLA General Hospital北京医院页面
  5. 研究中心复旦大学附属肿瘤医院Fudan University Shanghai Cancer Center上海医院页面
  6. 研究中心福建省肿瘤医院Fujian Cancer Hospital福州医院页面
  7. 研究中心河南省肿瘤医院Henan Cancer Hospital郑州医院页面
  8. 研究中心江西省肿瘤医院Jiangxi Cancer Hospital南昌医院页面
  9. 研究中心Nanchang People's Hospital南昌医院页面
  10. 研究中心山东省肿瘤医院Shandong Cancer Hospital and Institute济南医院页面
  11. 研究中心空军军医大学西京医院Xijing Hospital西安医院页面
  12. 研究中心云南省肿瘤医院Yunnan Cancer Hospital昆明医院页面
  13. 研究中心浙江省肿瘤医院Zhejiang Cancer Hospital杭州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT05950945,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Must agree to provide a newly obtained or archival baseline biopsy from primary and/or metastatic lesion.

    入选标准第 2 条

    Pathologically documented Breast Cancer (BC) tumor

    入选标准第 3 条

    Was never previously HER2-positive (IHC 3+ or IHC 2+/ISH+) on prior pathology testing (per ASCO CAP guidelines).

    入选标准第 8 条

  3. Was never previously treated with anti-HER2 therapy in the metastatic setting.

    入选标准第 9 条

    Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to Grade ≤1 or baseline.

    排除标准第 12 条

  4. Has an Eastern Cooperative Oncology Group performance status of 0 or 1.

    入选标准第 17 条

  5. Has multiple primary malignancies within 3 years, except adequately resected non-melanoma skin cancer, curatively treated in situ disease, other solid tumors curatively treated, or contralateral BC.

    排除标准第 6 条

  6. Is pregnant or breastfeeding or planning to become pregnant.

    排除标准第 13 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT05950945,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Sign and date the main informed consent form
  2. Must agree to provide a newly obtained or archival baseline biopsy from primary and/or metastatic lesion.
  3. Pathologically documented Breast Cancer (BC) tumor
  4. Is unresectable and/or metastatic.
  5. Is hormone receptor-negative or hormone receptor-positive.
  6. Must include percentage of positively stained cells to characterize if hormone receptor-positive or -negative.
  7. Has confirmed HER2 IHC 1+ or IHC 2+/ISH- (HER2-low) status or HER2 IHC 0 status as determined according to ASCO CAP 2018 guidelines1 based on sample collected during Tissue Screening as described above.
  8. Was never previously HER2-positive (IHC 3+ or IHC 2+/ISH+) on prior pathology testing (per ASCO CAP guidelines).
  9. Was never previously treated with anti-HER2 therapy in the metastatic setting.
  10. Has had at least one and up to two prior lines of therapy in the metastatic setting.
  11. In participants with hormone receptor-positive HER2-low metastatic BC (Cohort 3):
  12. Has recurrent disease <2 years from the initiation of adjuvant ET OR
  13. Has disease progression on CDK4/6 inhibitor-based regimen within 12 months of completion of adjuvant therapy with a CDK4/6 inhibitor OR
  14. Has disease progression within the first 12 months of CDK4/6 in the first line metastatic setting
  15. Presence of at least one measurable lesion based on computed tomography or magnetic resonance imaging.
  16. Participants with brain metastases are allowed in the study. The brain lesion(s) should be small (<2 cm), untreated, asymptomatic, not requiring urgent medical intervention, and are asymptomatic and clinically stable.
  17. Has an Eastern Cooperative Oncology Group performance status of 0 or 1.
  18. Has a minimum life expectancy of 12 weeks at Screening.
  19. Has a left ventricular ejection fraction ≥50% within 28 days before enrollment.
  20. Has adequate organ and bone marrow function within 28 days before enrollment.
  21. Has adequate treatment washout period before enrollment.
  22. Male and female subjects of reproductive/childbearing potential must agree to use a highly effective form of contraception.

排除标准:Exclusion Criteria:

  1. Prior treatment with an antibody drug conjugate (ADC).
  2. Uncontrolled or significant cardiovascular disease.
  3. Has a corrected QT interval prolongation.
  4. Has a history of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening.
  5. Has spinal cord compression or clinically active central nervous system metastases.
  6. Has multiple primary malignancies within 3 years, except adequately resected non-melanoma skin cancer, curatively treated in situ disease, other solid tumors curatively treated, or contralateral BC.
  7. Has a history of severe hypersensitivity reactions to either the drug substances or inactive ingredients in the drug product.
  8. Has a history of severe hypersensitivity reactions to other monoclonal antibodies.
  9. Has an uncontrolled infection requiring intravenous (IV) antibiotics, antivirals, or antifungals.
  10. Active primary immunodeficiency, known uncontrolled active human immunodeficiency virus (HIV) infection, or active hepatitis B or C infection.
  11. Has history of receiving a live, attenuated vaccine (messenger RNA and replication-deficient adenoviral vaccines are not considered attenuated live vaccines) within 30 days prior to the first exposure to study drug.
  12. Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to Grade ≤1 or baseline.
  13. Is pregnant or breastfeeding or planning to become pregnant.
  14. Lung-specific intercurrent clinically significant illnesses.
  15. Any autoimmune, connective tissue, or inflammatory disorders.
  16. Prior complete pneumonectomy.

引自 ClinicalTrials.gov, NCT05950945, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT05950945,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT05950945